Clinical Trial Update: Safety and Efficacy Study of GR68755 (Alosetron Hydrochloride) to Treat Severe Diarrhea-Predominant Irritable Bowel Syndrome (IBS) [Phase 2]

View source ↗

Summary

Phase 2 safety and efficacy study of GR68755 (alosetron hydrochloride) for severe diarrhea-predominant irritable bowel syndrome has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Irritable Bowel Syndrome
• Irritable Bowel Syndrome Diarrhea Predominant

Drugs mentioned

• Alosetron hydrochloride (Alosetron hydrochloride)

Snippet

Sponsor: GlaxoSmithKline | Conditions: Irritable Colon | Phase 2 | Status: COMPLETED